Jan 6 (Reuters) - Variant Bio, a private biotech firm, said on Tuesday it has launched a platform that uses artificial intelligence on genetic data to discover new drug candidates to send into human ...

Reflections of this month’s JP Morgan Week when many of the Life Sciences world of companies, investors and commentators ...

The annual 'letter' from Neal Mohan outlines the platform roadmap for 2026 with 4 priorities and themes that video marketers ...

Energy-efficient homes with HERS ratings show lower DTI and default risk when energy savings are factored into loans.

Learn 15 practical ways to improve Google Ads conversion rates, covering bidding, targeting, ad copy, and landing page ...

Artificial intelligence is moving quickly into drug discovery as pharmaceutical and biotech companies look for ways to cut years off R&D timelines and increase the chances of success amid rising costs ...

Bio-Rad Laboratories, Inc. engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. It operates through the ...

In this feature, we take a deeper look into the field of technology in higher education through the perspective of the ...

After reaching their peaks in late November, both the BioWorld Drug Developers Index and the Nasdaq Biotechnology Index finished the year slightly down from those highs. Full-year biopharma deal value ...

Waabi has secured a $750 million Series C round to accelerate autonomous trucking, and another roughly $250 million ...